You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a Diagnostic Test for Eosinophilic Chronic Rhinosinusitis

    SBC: GLYCOMIRA, LLC            Topic: NIAID

    PROJECT SUMMARYThe goal of this proposal is to optimize and clinically validate a new diagnostic test for eosinophilic chronic rhinosinusitis (eCRS) at the point-of-care, improving the efficiency, value, and accessibility of personalized medicine. eCRS affects up to 5 million Americans and is characterized by varying degrees of sinonasal and peripheral eosinophilia, linked to treatment responsiven ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. A Precision Medicine for Alcohol-Associated Liver Disease

    SBC: GENETOBE INC            Topic: 150

    ABSTRACT The goal of this study is to develop an RNAi-based genetic precision medicine to treat alcohol associated liver disease (AALD). AALD is a devastating health problem worldwide, accounts for the majority of alcohol-related mortality globally and is the second most indication for liver transplantation in the US. The current medical management for AALD remains limited, and no proven pathobiol ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Controlled Gradient Release of Biologics: Enhanced Nerve Conduit for Long‐Gap Injury Repair

    SBC: Pioneer Neurotech Inc.            Topic: 106

    Project Summary / Abstract Nerve injuries arising from trauma, disease, or as a surgical necessity, lead most often to permanent loss of some or all functions mediated by the injured nerves. 50,000 peripheral nerve procedures are performed every year in the US, and 300,000 across Europe. After complete transection of a nerve, the optimal clinical procedure for nerve repair remains the surgical end ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Development of the HC2099 series of MmpL3 inhibitors to treat tuberculosis

    SBC: TARN BIOSCIENCES, INC.            Topic: NIAID

    Tarn Biosciences, Inc. is a start-up pharmaceutical company headquartered in East Lansing, Michigan. The company is developing new therapies for tuberculosis (TB). The goal of this STTR is to develop the MmpL3 inhibitor, HC2099, as a new treatment for drug susceptible and multidrug-resistant TB (MDR-TB). In 2019, 10 million people worldwide fell ill to TB with ~ 1.4 million lives lost. Standard-of ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Leptospirosis Vaccine Development

    SBC: Luna Bioscience, Inc.            Topic: NIAID

    Summary/abstract. Leptospirosis is a globally important neglected disease caused by pathogenic Leptospira. It is estimated to cause more than 1 million global cases annually with a 5-20% case-fatality rate, significant morbidity, and important public health consequences. Currently there is no safe and effective vaccine to prevent human leptospirosis. LeptoX, Inc. proposes to develop the first huma ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Therapeutic Agents Targeting Cryptococcal Infections

    SBC: Quercus Molecular Design, LLC            Topic: NIAID

    Cryptococcus species are a clinically important group of opportunistic fungal pathogens that can cause life threatening disease, particularly in the immunocompromised patient population. Historically, this has involved patients with advanced HIV, but is becoming more prevalent in other immunovulnerable populations. The primary pathogens, C. neoformans and C. gattii, are ubiquitous in the environme ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. A Novel Technology to Disseminate WOOP (Wish, Outcome, Obstacle, Plan) to Dementia Caregivers

    SBC: BORROW MY GLASSES LLC            Topic: NIA

    1 Approximately 6.5 million Americans aged 65 and older live with dementia, supported by more than 11 million2 unpaid family caregivers. These numbers are projected to rise exponentially in the coming decades fueling the3 need to develop scalable ways to support dementia caregivers. The need to empower dementia caregivers to4 continue providing care while maintaining their own health and well-bein ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. A novel platform for synthetic generation and statistical obfuscation of tabular clinical data, simulated images, and machine-generated text

    SBC: GRAYRAIN, LLC            Topic: NCATS

    PROJECT SUMMARY Data is a critical and highly valuable commodity, driving meaningful change in our society, especially when it pertains to patient care and biomedical research. Currently, institutions pay inordinate sums to increase, regain, and complement their data panels. As an extra burden, data legislation and privacy protection regulations introduce barriers to forming effective partnerships ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Developing Active Stimulation and Monitoring Technologies to Optimize Pain and Nociception Management During Regional Anesthesia, General Anesthesia, and Post-Operative Care

    SBC: PASCALL Systems, Incorporated            Topic: 106

    Project Summary Surgery and acute post-operative pain are major contributors to persistent pain, chronic pain, and opioid dependence. Currently, there are no products on the market in the United States that can be used to monitor surgical nociception. Existing products use indicators that are susceptible to intraoperative influences such as blood loss, anesthetic drugs and antihypertensives. This ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Developing a virtual reality guided acupuncture imagery treatment for Chronic low back pain

    SBC: MASSACHUSETTS NEURO TECHNOLOGY, INC.            Topic: NCCIH

    Project Summary Low back pain (LBP) is one of the most common reasons for physician visits in the USA. A substantial number of chronic LBP (cLBP) patients do not adequately respond to current treatment options. Thus, the development of new treatments for cLBP is urgently needed. The use of imagery to treat illness, including chronic pain, is one of the oldest medical practices. Although still unde ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government